$1.41
0[0.00%]
At close: Apr 25
$1.41
0[0.00%]
PreMarket: 4:20PM EDT
Cue Biopharma
(NASDAQ:CUE)Latest News for Cue Biopharma Stock (NASDAQ:CUE)
Cue Biopharma Stock (NASDAQ: CUE)
Categories: All
Tuesday, April 09, 2024
- Forecasting The Future: 4 Analyst Projections For Cue BiopharmaBenzinga Insights - Apr 9, 2024, 10:01AM
- Stifel Maintains Buy on Cue Biopharma, Maintains $8 Price TargetBenzinga Newsdesk - Apr 9, 2024, 8:46AM
- Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price TargetBenzinga Newsdesk - Apr 9, 2024, 8:22AM
Monday, April 08, 2024
Wednesday, April 03, 2024
Wednesday, March 13, 2024
- Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Mar 13, 2024, 1:18PM
- Cue Biopharma shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and $6 price target.Benzinga Newsdesk - Mar 13, 2024, 9:29AM
- Jefferies Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $6Benzinga Newsdesk - Mar 13, 2024, 9:02AM
Monday, January 01, 2024
Thursday, November 09, 2023
Monday, November 06, 2023
Friday, November 03, 2023
Tuesday, October 03, 2023
Monday, October 02, 2023
Wednesday, August 30, 2023
Wednesday, August 09, 2023
Wednesday, July 26, 2023
- Cue Biopharma SVP Awarded $284K Worth of Stock OptionsBenzinga Insights - Jul 26, 2023, 11:01AM
- Chief Executive Officer at Cue Biopharma Acquires Company Stock Options Worth 450,000 SharesBenzinga Insights - Jul 26, 2023, 11:01AM
- Cue Biopharma Chief Medical Officer Awarded $312K Worth of Stock OptionsBenzinga Insights - Jul 26, 2023, 11:01AM
- Cue Biopharma Chief Financial Officer Awarded $428K Worth of Stock OptionsBenzinga Insights - Jul 26, 2023, 11:00AM
Monday, June 26, 2023
Thursday, June 15, 2023
Monday, May 15, 2023
Wednesday, March 22, 2023
- Cue Biopharma Earnings Perspective: Return On Capital EmployedBenzinga Insights - Mar 22, 2023, 10:46AM
- Stifel Maintains Buy on Cue Biopharma, Lowers Price Target to $8Benzinga Newsdesk - Mar 22, 2023, 10:45AM
- Oppenheimer Reiterates Outperform on Cue Biopharma, Maintains $10 Price TargetBenzinga Newsdesk - Mar 22, 2023, 7:28AM
Tuesday, March 21, 2023
Monday, March 20, 2023
Wednesday, February 22, 2023
Monday, November 21, 2022
Monday, November 14, 2022
Monday, October 24, 2022
Tuesday, October 04, 2022
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Oct 4, 2022, 1:53PM
- Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Oct 4, 2022, 12:41PM
- Cue Biopharma Granted FDA Fast Track Designation For CUE-101 For The Treatment Of Recurrent/Metastatic Head And Neck Squamous Cell CarcinomaBenzinga Newsdesk - Oct 4, 2022, 8:01AM
Monday, October 03, 2022
Thursday, September 01, 2022
Wednesday, August 24, 2022
Monday, August 22, 2022
- Recap Of Monday's Biotech Catalysts - End Of the Day SummaryRagothaman Srinivasan - Aug 22, 2022, 7:10PM
- Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-offRagothaman Srinivasan - Aug 22, 2022, 11:17AM
- Cue Biopharma Doses First Patient In Phase 1 Study Of CUE-102 For Wilms' Tumor 1 (WT1)Benzinga Newsdesk - Aug 22, 2022, 8:08AM